Benjamin Chastek, MS
Benjamin Chastek joined Optum in 2004 and is the therapeutic lead for HEOR studies involving immunology. He oversees research, data acquisitions and study execution.
Since 2008, he has focused on research related to rheumatoid arthritis, psoriasis, psoriatic arthritis and other autoimmune disorders.
Chastek has a Master of Science in statistics from Minnesota State University, where he specialized in theoretical and computational statistics. Prior to becoming a therapeutic lead, he was a researcher within Optum with a specific expertise on large claims datasets.
Some of the areas in which he is well versed in include survival analysis, longitudinal or panel data sets, and cost analysis, including the presence of right censoring.
His research has been presented at a number of national and international conferences and in numerous journals including the American College of Rheumatology and American Journal of Pharmacy Benefits.
Majethia S, Lee I, Chastek B, Bunner S, Wolf J, Hsiao A, Mozaffari E. Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C. J Manag Care Spec Pharm, 2022 Jan;28(1):48-57.
Chastek B, Segal S, Bonafede RP, Watson C, Becker L, Chaudhari S, Harrison DJ, Gandra SR. Comparative Effectiveness of TNF Blockers in Rheumatoid Arthritis Patients. Am J Pharm Benefits. 2013;5(Special Issue):SP14-SP22.
Chastek B, Kulakodlu M, Valluri S, Seal B. Impact of Metastatic Colorectal Cancer Stage and Number of Treatment Courses on Patient Health Care Costs and Utilization. Postgrad Med. 2013 Mar;125(2):73-82.
Chastek B, Harley C, Kallich J, Newcomer L, Paoli C, Teitelbaum A. Health Care Costs for Patients With Cancer at the End of Life. J Oncol Pract. 2012 Nov;8(6):75s-80s.
Pollack M, Chastek B, Williams S, Moran J. Impact of treatment complexity on adherence and glycemic control: An analysis of oral antidiabetic agents. JCOM. 2010 Jun; 17(6), 257-265.
Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13(4):618-25.
HEOR, Health Economics Outcomes Research, Health Economics, Immunology